Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Colleague Insights
Grand Rounds
Conferences
Video Expert Opinion
Living Resources
Sign in
Join now
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
Nekesha Oliphant MD
Nekesha Oliphant MD Advisory Board
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
See All Experts
featured
Published in Primary Care and
3 other channels

Journal Scan / Research · October 12, 2021

Improved Cardiovascular Outcomes Associated With SGLT2 Inhibitors vs GLP-1 Receptor Agonist in Patients With Diabetes

Annals of Internal Medicine

 

 Save  Recommend
 Share

Additional Info

Annals of Internal Medicine
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Ann. Intern. Med 2021 Sep 28;[EPub Ahead of Print], E Patorno, PT Htoo, RJ Glynn, S Schneeweiss, DJ Wexler, A Pawar, LG Bessette, K Chin, BM Everett, SC Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated